arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

IDEXX LABORATORIES INC /DE

IDXX
$590.17 ▲ +5.48 (+0.94%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
71 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

IDEXX LABORATORIES INC /DE shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $47.0B
Dividend Yield
Revenue Growth 14.3%
Op. Margin 31.8%
ROIC 15.3%
FCF / Share $2.94
Trailing P/E 168.6x
Price / Book 30.1x
FCF Yield 0.5%
Debt / Equity 0.19
info Valuation on last close. End-of-day price, Aug 6, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.14B
↑ +14.3%
Net Income Profit after all expenses
$278.45M
↑ +14.7%
Operating Margin Operating profit as % of sales
31.8%
↑ +9.8% 88th
FCF / Share Free cash flow per share
$2.94
↑ +15.0%
Long-Term Debt Long-term obligations
$299.85M
↓ -33.4%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
87
Returns
98
Financial Health
79
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 71 quarters